REPORT ID 8222

EMEA (Europe, Middle East and Africa) Nuclear Medicine & Radio Pharmaceuticals Market Report 2017

Publish Date
7-Nov-17
Pages
108
Format
Electronic (PDF)

In this report, the EMEA Nuclear Medicine & Radio Pharmaceuticals market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Nuclear Medicine & Radio Pharmaceuticals for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Nuclear Medicine & Radio Pharmaceuticals market competition by top manufacturers/players, with Nuclear Medicine & Radio Pharmaceuticals sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    GE Healthcare
    Philips Healthcare
    Siemens Healthcare
    Toshiba
    Hitachi
    Carestream
    Esaote
    Shimadzu
    TriFoil Imaging
    Biosensors International Group, Ltd

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Diagnostic Medicine: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
    Therapeutic Medicine: Beta Emitters, Alpha Emitters, Brachytherapy Isotopes

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Diagnostic Applications: SPECT, PET.
    Therapeutic Applications: Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Therapeutic Applications.

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Nuclear Medicine & Radio Pharmaceuticals Market Report 2017
1 Nuclear Medicine & Radio Pharmaceuticals Overview
    1.1 Product Overview and Scope of Nuclear Medicine & Radio Pharmaceuticals
    1.2 Classification of Nuclear Medicine & Radio Pharmaceuticals
        1.2.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Diagnostic Medicine: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
        1.2.4 Therapeutic Medicine: Beta Emitters, Alpha Emitters, Brachytherapy Isotopes
    1.3 EMEA Nuclear Medicine & Radio Pharmaceuticals Market by Application/End Users
        1.3.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Diagnostic Applications: SPECT, PET.
        1.3.3 Therapeutic Applications: Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Therapeutic Applications.
    1.4 EMEA Nuclear Medicine & Radio Pharmaceuticals Market by Region
        1.4.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Nuclear Medicine & Radio Pharmaceuticals (2012-2022)
        1.5.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Revenue and Growth Rate (2012-2022)

2 EMEA Nuclear Medicine & Radio Pharmaceuticals Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Market Competition by Players/Manufacturers
        2.1.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Nuclear Medicine & Radio Pharmaceuticals Sale Price by Players (2012-2017)
    2.2 EMEA Nuclear Medicine & Radio Pharmaceuticals (Volume and Value) by Type/Product Category
        2.2.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Nuclear Medicine & Radio Pharmaceuticals Sale Price by Type (2012-2017)
    2.3 EMEA Nuclear Medicine & Radio Pharmaceuticals (Volume) by Application
    2.4 EMEA Nuclear Medicine & Radio Pharmaceuticals (Volume and Value) by Region
        2.4.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales Price by Region (2012-2017)

3 Europe Nuclear Medicine & Radio Pharmaceuticals (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Nuclear Medicine & Radio Pharmaceuticals Sales and Value (2012-2017)
        3.1.1 Europe Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Nuclear Medicine & Radio Pharmaceuticals Revenue and Growth Rate (2012-2017)
    3.2 Europe Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Type
    3.3 Europe Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Application
    3.4 Europe Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Nuclear Medicine & Radio Pharmaceuticals Sales Volume by Countries (2012-2017)
        3.4.2 Europe Nuclear Medicine & Radio Pharmaceuticals Revenue by Countries (2012-2017)
        3.4.3 Germany Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        3.4.4 France Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        3.4.5 UK Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        3.4.6 Russia Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        3.4.7 Italy Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)

4 Middle East Nuclear Medicine & Radio Pharmaceuticals (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Nuclear Medicine & Radio Pharmaceuticals Sales and Value (2012-2017)
        4.1.1 Middle East Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Nuclear Medicine & Radio Pharmaceuticals Revenue and Growth Rate (2012-2017)
    4.2 Middle East Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Type
    4.3 Middle East Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Application
    4.4 Middle East Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Nuclear Medicine & Radio Pharmaceuticals Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Nuclear Medicine & Radio Pharmaceuticals Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        4.4.4 Israel Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        4.4.5 UAE Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        4.4.6 Iran Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)

5 Africa Nuclear Medicine & Radio Pharmaceuticals (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Nuclear Medicine & Radio Pharmaceuticals Sales and Value (2012-2017)
        5.1.1 Africa Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Nuclear Medicine & Radio Pharmaceuticals Revenue and Growth Rate (2012-2017)
    5.2 Africa Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Type
    5.3 Africa Nuclear Medicine & Radio Pharmaceuticals Sales and Market Share by Application
    5.4 Africa Nuclear Medicine & Radio Pharmaceuticals Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Nuclear Medicine & Radio Pharmaceuticals Sales Volume by Countries (2012-2017)
        5.4.2 Africa Nuclear Medicine & Radio Pharmaceuticals Revenue by Countries (2012-2017)
        5.4.3 South Africa Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate (2012-2017)

6 EMEA Nuclear Medicine & Radio Pharmaceuticals Manufacturers/Players Profiles and Sales Data
    6.1 GE Healthcare
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 GE Healthcare Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Philips Healthcare
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Philips Healthcare Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Siemens Healthcare
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Siemens Healthcare Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Toshiba
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Toshiba Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Hitachi
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Hitachi Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Carestream
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Carestream Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Esaote
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Esaote Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Shimadzu
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Shimadzu Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 TriFoil Imaging
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 TriFoil Imaging Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Biosensors International Group, Ltd
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Nuclear Medicine & Radio Pharmaceuticals Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Biosensors International Group, Ltd Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Nuclear Medicine & Radio Pharmaceuticals Manufacturing Cost Analysis
    7.1 Nuclear Medicine & Radio Pharmaceuticals Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Nuclear Medicine & Radio Pharmaceuticals

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Nuclear Medicine & Radio Pharmaceuticals Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Nuclear Medicine & Radio Pharmaceuticals Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Nuclear Medicine & Radio Pharmaceuticals Market Forecast (2017-2022)
    11.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Nuclear Medicine & Radio Pharmaceuticals Price and Trend Forecast (2017-2022)
    11.2 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Nuclear Medicine & Radio Pharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales Forecast by Type (2017-2022)
    11.7 EMEA Nuclear Medicine & Radio Pharmaceuticals Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer